AstraZeneca’s MedImmune, Sanofi partner to develop infant respiratory drug
Under the deal, the companies will jointly develop and commercialise MEDI8897, a highly potent monoclonal antibody (mAb) that neutralises RSV by binding the RSV fusion (F) protein expressed on